IL42016A - Dopamine derivatives and their preparation - Google Patents

Dopamine derivatives and their preparation

Info

Publication number
IL42016A
IL42016A IL42016A IL4201673A IL42016A IL 42016 A IL42016 A IL 42016A IL 42016 A IL42016 A IL 42016A IL 4201673 A IL4201673 A IL 4201673A IL 42016 A IL42016 A IL 42016A
Authority
IL
Israel
Prior art keywords
methyl
hydrogen
phenethylamine
methoxylated
propyl7
Prior art date
Application number
IL42016A
Other languages
Hebrew (he)
Other versions
IL42016A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22918877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL42016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL42016A0 publication Critical patent/IL42016A0/en
Publication of IL42016A publication Critical patent/IL42016A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1392674 Dopamine derivatives ELI LILLY & CO 9 April 1973 [12 April 1972] 16835/73 Heading C2C The invention comprises dopamine derivatives of Formula (I) in which R and R 1 are H or CH 3 , at least one being H; R 2 and R 3 are H or OH at least one being OH; n is 1 or 2; and when n is 1 and R 2 and R 3 are both OH, then either R or R 1 is CH 3 ; and the pharmaceutically acceptable addition salts thereof with mineral acids. They may be prepared by reacting a compound of Formula (II) in which R 1 is hydrogen, R 2 <SP>1</SP> and R 3 <SP>1</SP> are H or CH 3 O- at least one being methoxy, n is 1 or 2; and when n is 1 and R2<SP>1</SP> and R 3 <SP>1</SP> are both CH 3 O, then R or R 1 is CH 3 ; with hydrobromic acid and optionally converting to pharmaceutically acceptable salts. The methyl ethers used as starting materials may be prepared as follows: (a) the compounds of Formula II in which R is methyl and R 1 is hydrogen are prepared by the reductive alkylation of a methoxylated phenylethylamine or a methoxylated phenyl propyl amine with 3,4-dimethoxyphenylacetone; (b) the compounds in which R is methyl and R 1 is hydrogen may also be prepared by reacting 3,4- dimethoxyphenylacetone with a methoxylated phenethylamine or a methoxylated phenylpropylamine in the presence of p-toluene sulphonic acid to form the imine which is then reduced to the secondary amine; (c) the compounds in which R is hydrogen and R 1 is methyl may be prepared by the reductive alkylation of 3,4-dimethoxyphenylethylamine with the desired mono- or dimethoxylated phenyl butane-3-one (n=2) or the mono- or di-methoxylated phenylacetone (n = 1); (d) the compounds in which R is hydrogen and R 1 is methyl may also be prepared by the condensation of 3,4-dimethoxyphenylacetic acid with a methoxylated 1 -phenyl-3-aminobutane (n=2) or with a methoxylated 1-phenyl-2- aminopropane (n =1) to form as an intermediate the methoxylated amide which is reduced under nitrogen with borane to provide the secondary amine; and (e) the compounds in which R and R 1 are both hydrogen may be prepared by the alkylation of 3,4-dimethoxyphenylethylamine with a methoxylated phenyl-n-propyl bromide (n=2) or with a methoxylated phenyethyl bromide (n= 1). The products of Formula (I) are used in pharmaceutical agents. [GB1392674A]

Claims (10)

1. The dopamine derivative compound of the formula I wherein R and R]_ are hydrogen or methyl, at least one of R or R-. being hydrogen; R„ and R~ are hydrogen or hydroxy, J. at least one of R2 or ^ being hydroxy; n is 1 or 2; and when n is 1 and 2 and are both hydroxy then either R and is methyl; and when R is methyl, then 2 and are both hydroxy; and the pharmaceutically acceptable acid addition salts thereof with mineral acids.
2. The dopamine compound of claim 1 wherein said compound is 3,^-cLihydroxy-N-/ 3-(^-hydroxyphenyl)- l-methyl-n-propyl7^rPhenethylamine hydrochloride; 1-3,4- dihydroxy-N- "3-( -hydroxyphenyl)-l-methyl-n-propyl7- β- henθthylamine hydrochloride; 3, -d ihydroxy-N- "3- (3-^ydroxyphenyl ) -n- or propyl7- -Phenethylamine hydrochloride ; /3, ½-d ihydroxy-N-Z"3- ( 3 , ^-dihydroxyphenyl ) -n-propyl-p-phenethylamine hydro-chlorida.
3. A process for preparing the dopamine derivative compounds of Claim 1 which comprises reacting a com- 42016/2 FORMULA II wherein R and are hydrogen or methyl, at least one of R or RL being hydrogen;- and R^ are hydrogen or methoxy, at least one of R or R^ being methoxy; n is 1 or 2; and when n is 1 and R and ^ are both methox , then either R or Rx is methyl; and when R is methyl, then R and ^ are both methoxy; with hydrobromic acid and optionally converting to the pharmaceutically acceptable salts.
4. The process according to claim 3 which comprises refluxing the methoxy secondary amine of formula II with concentrated hydrobromic acid in the presence of an inert solvent.
5. · The process according to claim 3 or for preparing 3 , -dihydroxy-N- ~3- ( -hydroxyphenyl )-l-methyl- n-propyl7- -Phenethylamine which comprises catalyt ically hydrogenating a reaction mixture containing 1- ( -methoxy- phenyl)-3-butanone and homoveratrylamine in an inert solvent, to form 3, -dimethoxy-N- **3-(i).»inethoxyphenyl)-l-- methyl-n-propyl7-phenethylamine and reacting the trimethoxy secondary amine thus obtained with hydrobromic acid,
6. The process according to claim 3 or which comprises reacting 3-(^-methoxyphenyl)-l-methyl-n-propyl-, amine and acid, reducing the 42016/2 2- (3,^-dimethoxyphenyl)-N^ (^-methoxyphenyl-l-methyl-n-propyDacetamide thus obtained with borane, and reacting the resulting 3 ,iv-dimethoxy-N- ~3- ( -methoxyphenyl ) -1-methyl-n,-propyl7-P-phenethylamine with hydrobromic acid,
7. A process according to claim 3 or for pre¬ y-phenyl propenyl ketone with homoveratrylamine in the presence of an inert solvent, catalytically hydrogenating the 3- ( 3 , dimethoxyphenylethylamino ) -1- ( -methoxyphenyl ) -butane-l-one thus obtained, precipitating as a product ·" Uie catalytic hydrogenation 3,^-dimethoxy-N-(~3-( -me hoxyphenyl)-l-methyl-n-propyl7-P-phenethylamine hydrochloride, and treating the product with hydrogen bromide.
8. A process according to claim 3 or ^ for preparing 3 , ( 3-hydroxyphenyl ) -n-propyl7-β-phenethylamine which comprises reacting 3 , -dimethoxy-phenethylamine and 3-(3-methoxyphenyl)-n-propyl bromide, and treating the 3,^-dimethoxy-N- ~3-(3-methoxyphenyl-n-propyl7- -phenethylamine thus obtained with hydrogen bro-mide. 42016/2
9. A process according to claim 3 or for preparing 3,4-dihydroxy-N- ~3-(3,^-dihydroxyphenyl-n- propyl7- -phenethylamine which comprises reacting 3 - dimethoxyphenethylamine and p-(3„4-dimethoxyphenyl)- propionic acid, reducing the N-(3,^-dimethoxyphenyl- ethyl-3 , -dimethoxyphenylpropionamide thus obtained with borane, and reacting the resulting 3,i4—dimethoxy-N- ~3- (3,^-dimethoxyphenyl ) -n-propyl7-P-phenethylamine with hy- drobromic acid.
10. A process according to any of the preced- ing claims which comprises resolving a racemic mixture of a compound of formula II, and then individually reacting the resolved d- and 1- amines with hydrobromic acid to obtain the corresponding d- and 1,-phenolic amines. ND/rb
IL42016A 1972-04-12 1973-04-12 Dopamine derivatives and their preparation IL42016A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24346672A 1972-04-12 1972-04-12

Publications (2)

Publication Number Publication Date
IL42016A0 IL42016A0 (en) 1973-06-29
IL42016A true IL42016A (en) 1976-05-31

Family

ID=22918877

Family Applications (1)

Application Number Title Priority Date Filing Date
IL42016A IL42016A (en) 1972-04-12 1973-04-12 Dopamine derivatives and their preparation

Country Status (31)

Country Link
JP (2) JPS5825656B2 (en)
KR (1) KR790000113B1 (en)
AR (1) AR203822A1 (en)
AT (1) AT323719B (en)
AU (1) AU472734B2 (en)
BE (1) BE798051A (en)
BG (1) BG23001A3 (en)
CA (1) CA1018188A (en)
CH (2) CH569691A5 (en)
CS (2) CS190406B2 (en)
CY (1) CY963A (en)
DD (1) DD107670B3 (en)
DE (1) DE2317710C2 (en)
DK (1) DK142750C (en)
ES (1) ES413639A1 (en)
FR (1) FR2182947B1 (en)
GB (1) GB1392674A (en)
HK (1) HK50178A (en)
HU (2) HU167597B (en)
IE (1) IE37511B1 (en)
IL (1) IL42016A (en)
KE (1) KE2870A (en)
MY (1) MY7800381A (en)
NL (1) NL174459C (en)
PH (1) PH11041A (en)
PL (2) PL94207B1 (en)
RO (2) RO70892A (en)
SE (1) SE399064B (en)
SU (1) SU496719A3 (en)
YU (2) YU36483B (en)
ZA (1) ZA732136B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585693A5 (en) * 1974-02-08 1977-03-15 Ciba Geigy Ag
US4342692A (en) * 1980-10-20 1982-08-03 Usv Pharmaceutical Corporation Pyrrolidines
ES8702355A1 (en) * 1981-07-22 1985-07-01 Syntex Inc Substituted pyrrolidine cardiovascular system regulators and antihypertensives, their preparation and use.
JPS6061523A (en) * 1983-09-16 1985-04-09 Shionogi & Co Ltd Oral dobutamine pharmaceutical
IL85438A0 (en) * 1987-02-24 1988-07-31 Lilly Co Eli Improvements in or relating to dobutamine salts
JPH0383364U (en) * 1989-12-18 1991-08-23
CA2103367A1 (en) * 1991-05-20 1992-11-21 Akihide Koda Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
EP0620208B1 (en) * 1993-04-13 1997-07-09 Duphar International Research B.V Production of dobutamine compounds
DE69404063T2 (en) * 1993-04-13 1998-01-22 Duphar Int Res Manufacture of dobutamine compounds
AU2003274605A1 (en) 2002-10-03 2004-04-23 Novaremed Ltd Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
CA2560922C (en) 2004-03-26 2014-01-07 New Era Biotech, Ltd. Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
WO2011014880A1 (en) 2009-07-31 2011-02-03 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
CN104053435A (en) * 2011-08-25 2014-09-17 考格尼申治疗股份有限公司 Compositions and methods for treating neurodegenerative disease
DK3498692T3 (en) 2014-01-31 2022-05-16 Cognition Therapeutics Inc Isoindoline compositions and methods for treating neurodegenerative disease and macular degeneration
BR112019023851A2 (en) 2017-05-15 2020-08-18 Cognition Therapeutics, Inc. compounds, their pharmaceutical compositions and methods for treating neurodegenerative diseases
CN114524734B (en) * 2021-12-27 2024-04-26 嘉实(湖南)医药科技有限公司 Preparation method of dobutamine hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276619A (en) * 1942-03-17 N-phentlaliphatic-dihtoroxyphentnl

Also Published As

Publication number Publication date
MY7800381A (en) 1978-12-31
PL94207B1 (en) 1977-07-30
YU36483B (en) 1984-02-29
SE399064B (en) 1978-01-30
DE2317710A1 (en) 1973-10-18
CH580563A5 (en) 1976-10-15
KR790000113B1 (en) 1979-03-20
RO70892A (en) 1982-02-26
JPS6221343B2 (en) 1987-05-12
RO65105A (en) 1980-01-15
HU167597B (en) 1975-11-28
ZA732136B (en) 1974-03-27
AU5438573A (en) 1974-10-17
PH11041A (en) 1977-10-25
CS190406B2 (en) 1979-05-31
DK142750C (en) 1981-08-17
NL174459B (en) 1984-01-16
DK142750B (en) 1981-01-12
GB1392674A (en) 1975-04-30
DD107670A5 (en) 1974-08-12
IL42016A0 (en) 1973-06-29
AU472734B2 (en) 1976-06-03
JPS497237A (en) 1974-01-22
CS190448B2 (en) 1979-05-31
NL7305097A (en) 1973-10-16
DE2317710C2 (en) 1983-08-04
HK50178A (en) 1978-09-15
YU37113B (en) 1984-08-31
CY963A (en) 1978-12-22
FR2182947A1 (en) 1973-12-14
BG23001A3 (en) 1977-05-20
DD107670B3 (en) 1988-04-06
AR203822A1 (en) 1975-10-31
FR2182947B1 (en) 1976-07-02
CA1018188A (en) 1977-09-27
PL90695B1 (en) 1977-01-31
YU321279A (en) 1983-04-27
KE2870A (en) 1978-09-01
SU496719A3 (en) 1975-12-25
BE798051A (en) 1973-10-11
AT323719B (en) 1975-07-25
IE37511B1 (en) 1977-08-03
CH569691A5 (en) 1975-11-28
JPS5825656B2 (en) 1983-05-28
HU166213B (en) 1975-02-28
JPS58131945A (en) 1983-08-06
NL174459C (en) 1984-06-18
ES413639A1 (en) 1976-01-16
YU97673A (en) 1982-02-25

Similar Documents

Publication Publication Date Title
IL42016A (en) Dopamine derivatives and their preparation
AU594788B2 (en) Pyridine ethanolamine derivatives
Salvatore et al. Synthesis of secondary amines
Tang et al. Direct One‐Pot Reductive N‐Alkylation of Nitroarenes by using Alcohols with Supported Gold Catalysts
US5733936A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
US6632955B1 (en) Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US3551493A (en) Alkyl-and cycloalkyl-amino-propanol-cyclopentyl- and cyclopentenyl-phenol ethers
EP2285770B1 (en) Process for the synthesis of arformoterol
KR20010094764A (en) Monoamine Reuptake Inhibitors for Treatment of CNS Disorders
AU702776B2 (en) Use of aryl-substituted cyclobutylalkylamines for treating obesity
WO2008035358A2 (en) Process for preparing dapoxetine
US3987200A (en) Method for increasing cardiac contractility
IE894118L (en) An impoved process for the preparation of a valuable drug
MXPA02001372A (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives.
EP1601640A2 (en) Process for preparation of phenethylamine derivatives
CA1061357A (en) Phenylalkylamines
WO2023044027A1 (en) Preparation of optically active enantiomers of piperonyl amines by resolution of the diastereomeric salts
CA1171086A (en) Substituted 2-phenyl-ethylamines and isosteric compounds, process for their production and use
CA2396304A1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
US4028415A (en) Diphenylpropylamines
US2599001A (en) Nu, nu-disubstituted-beta-haloalkylamines
Chandrasekhar et al. Inexpensive protocol for reduction of imines to amines using polymethylhydrosiloxane (PMHS)
CN111777520B (en) Synthesis method of multi-substituted dimethylamino phenyl acetic acid compound
Krstić et al. Enantioselective organocatalytic addition of nitromethane to trifluoromethyl aryl ketimines promoted by electron‐rich bifunctional iminophosphoranes
US4918246A (en) Process for preparing optically active haloalcohols